An open-label, phase II study of the polo-like kinase-1 (P1k-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC) Article

Industry Collaboration International Collaboration

cited authors

  • Awad, Mark M.; Chu, Quincy S-C; Gandhi, Leena; Stephenson, Joe J.; Govindan, Ramaswamy; Bradford, Daniel S.; Bonomi, Philip D.; Ellison, David M.; Eaton, Keith D.; Fritsch, Holger; Munzert, Gerd; Johnson, Bruce E.; Socinski, Mark A.

authors

Publication Date

  • February 1, 2017

webpage

published in

category

keywords

  • BI 2536
  • Plk-1 inhibition
  • Polo-like kinase
  • Small cell lung cancer

start page

  • 126

end page

  • 130

volume

  • 104